Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 01 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)- Insider Own61.87% Shs Outstand40.82M Perf Week-0.47%
Market Cap1.13B Forward P/E- EPS next Y- Insider Trans8.90% Shs Float15.56M Perf Month-
Income- PEG- EPS next Q- Inst Own3.44% Short Float3.74% Perf Quarter-
Sales- P/S- EPS this Y- Inst Trans- Short Ratio0.77 Perf Half Y-
Book/sh-1.81 P/B- EPS next Y- ROA- Short Interest0.58M Perf Year-
Cash/sh1.26 P/C22.07 EPS next 5Y- ROE- 52W Range26.04 - 35.06 Perf YTD-7.50%
Dividend Est.- P/FCF- EPS past 5Y- ROI- 52W High-20.85% Beta-
Dividend TTM- Quick Ratio4.45 Sales past 5Y24.20% Gross Margin- 52W Low6.57% ATR (14)1.70
Dividend Ex-Date- Current Ratio4.45 EPS Y/Y TTM- Oper. Margin- RSI (14)- Volatility4.84% -
Employees- Debt/Eq0.23 Sales Y/Y TTM- Profit Margin- Recom- Target Price-
Option/ShortNo / Yes LT Debt/Eq0.18 EPS Q/Q- Payout- Rel Volume0.31 Prev Close27.17
Sales Surprise- EPS Surprise- Sales Q/Q- Earnings- Avg Volume757.89K Price27.75
SMA20-3.30% SMA50-3.30% SMA200-3.30% Trades Volume233,310 Change2.13%
KYVERNA is pioneering a new class of treatments and potential cures for serious autoimmune diseases. The company's therapeutic platform combines advanced T-cell engineering and synthetic biology technologies to suppress and eliminate the autoreactive immune cells at the root cause of inflammatory diseases.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GILEAD SCIENCES, INC.10% OwnerFeb 12Buy22.00910,00020,020,0004,126,119Feb 13 05:48 PM
Bain Capital Life Sciences Inv10% OwnerFeb 12Buy22.00450,0009,900,0003,163,868Feb 14 05:26 PM
Northpond Ventures III GP, LLCFormer 10% OwnerFeb 12Buy22.00450,0009,900,000450,000Feb 12 05:51 PM
Vida Ventures, LLC10% OwnerFeb 12Buy22.00253,1365,568,992252,553Feb 14 07:04 PM